CYP19A1 and Alzheimer disease: Additionally, older patients receiving the steroidal aromatase inhibitor exemestane had a statistically significant decrease in the incidence of AD and dementia compared with patients receiving the non-steroidal therapies anastrozole and letrozole (Branigan et al., 2020).